{
    "root": "1d7b4793-3f52-4731-8c78-78e258645157",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Imbruvica",
    "value": "20241220",
    "ingredients": [
        {
            "name": "IBRUTINIB",
            "code": "1X70OSD4VX"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        }
    ],
    "indications": "imbruvica kinase inhibitor indicated treatment : adult patients chronic lymphocytic leukemia ( cll ) /small lymphocytic lymphoma ( sll ) ( 1.1 ) . adult patients chronic lymphocytic leukemia ( cll ) /small lymphocytic lymphoma ( sll ) 17p deletion ( 1.2 ) . adult patients waldenström ’ macroglobulinemia ( wm ) ( 1.3 ) . adult pediatric patients age 1 year older chronic graft versus host disease ( cgvhd ) failure one lines systemic therapy ( 1.4 ) .",
    "contraindications": "cll/sll wm : 420 mg taken orally daily ( 2.1 ) . cgvhd : ◦ patients 12 years older : 420 mg taken orally daily ( 2.1 ) . ◦ patients 1 less 12 years age : 240 mg/m 2 taken orally daily ( dose 420 mg ) ( 2.1 ) . tablets capsules taken orally glass water . open , break , chew capsules . cut , crush , chew tablets . full prescribing information oral suspension instructions ( 2.1 ) .",
    "warningsAndPrecautions": "capsules 70 mg capsules supplied yellow opaque capsules , marked “ ibr 70 mg ” black ink , white hdpe bottles child-resistant closure : 28 capsules per bottle : ndc 57962-070-28 140 mg capsules supplied white opaque capsules , marked “ ibr 140 mg ” black ink , white hdpe bottles child-resistant closure : 90 capsules per bottle : ndc 57962-140-09 120 capsules per bottle : ndc 57962-140-12 store bottles room temperature 20°c 25°c ( 68°f 77°f ) . brief exposure 15°c 30°c ( 59°f 86°f ) permitted ( usp controlled room temperature ) . retain original package dispensing . tablets imbruvica ( ibrutinib ) tablets supplied 3 strengths following packaging configurations : 140 mg tablets : yellow green green round tablets debossed “ ibr ” one side “ 140 ” side . carton one folded blister card containing two 14-count blister strips total 28 tablets : ndc 57962-014-28 280 mg tablets : purple oblong tablets debossed “ ibr ” one side “ 280 ” side . carton one folded blister card containing two 14-count blister strips total 28 tablets : ndc 57962-280-28 420 mg tablets : yellow green green oblong tablets debossed “ ibr ” one side “ 420 ” side . carton one folded blister card containing two 14-count blister strips total 28 tablets : ndc 57962-420-28 store tablets original packaging room temperature 20°c 25°c ( 68°f 77°f ) . brief exposure 15°c 30°c ( 59°f 86°f ) permitted ( usp controlled room temperature ) . oral suspension imbruvica ( ibrutinib ) oral suspension white off-white suspension supplied 108 ml 150 ml amber glass bottle pre-inserted bottle adapter child-resistant closure . ml contains 70 mg ibrutinib . oral suspension bottle provided carton two 3 ml reusable oral dosing syringes : ndc 57962-007-12. store oral suspension bottle 2°c 25°c ( 36°f 77°f ) . freeze . dispense original sealed container . carton seal broken missing . discard unused imbruvica oral suspension remaining 60 days first opening bottle .",
    "adverseReactions": "none",
    "indications_original": "IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).",
    "contraindications_original": "CLL/SLL and WM : 420 mg taken orally once daily ( 2.1 ). cGVHD : ◦ Patients 12 years and older: 420 mg taken orally once daily ( 2.1 ). ◦ Patients 1 to less than 12 years of age: 240 mg/m 2 taken orally once daily (up to a dose of 420 mg) ( 2.1 ). Tablets or capsules should be taken orally with a glass of water. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets. See full prescribing information for oral suspension administration instructions ( 2.1 ).",
    "warningsAndPrecautions_original": "Capsules\n                  \n                  The 70 mg capsules are supplied as yellow opaque capsules, marked with “ibr 70 mg” in black ink, in white HDPE bottles with a child-resistant closure:\n                  \n                     28 capsules per bottle: NDC 57962-070-28\n                  \n                  The 140 mg capsules are supplied as white opaque capsules, marked with “ibr 140 mg” in black ink, in white HDPE bottles with a child-resistant closure:\n                  \n                     90 capsules per bottle:  NDC 57962-140-09\n                     \n                     120 capsules per bottle:  NDC 57962-140-12\n                  \n                  Store bottles at room temperature 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted (see USP Controlled Room Temperature). Retain in original package until dispensing.\n                  \n                     Tablets\n                  \n                  The IMBRUVICA (ibrutinib) tablets are supplied in 3 strengths in the following packaging configurations: \n                  \n                     140 mg tablets: Yellow green to green round tablets debossed with “ibr” on one side and “140” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-014-28\n                     \n                     280 mg tablets: Purple oblong tablets debossed with “ibr” on one side and “280” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-280-28 \n                     \n                     420 mg tablets: Yellow green to green oblong tablets debossed with “ibr” on one side and “420” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-420-28\n                  \n                  Store tablets in original packaging at room temperature 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted (see USP Controlled Room Temperature).\n                  \n                     Oral Suspension\n                  \n                  The IMBRUVICA (ibrutinib) oral suspension is a white to off-white suspension supplied as 108 mL in a 150 mL amber glass bottle with a pre-inserted bottle adapter and a child-resistant closure. Each mL contains 70 mg of ibrutinib. The oral suspension bottle is provided in a carton with two 3 mL reusable oral dosing syringes: NDC 57962-007-12.\n                  Store the oral suspension bottle at 2°C to 25°C (36°F to 77°F). Do not freeze. Dispense in original sealed container. Do not use if the carton seal is broken or missing.\n                  Discard any unused IMBRUVICA oral suspension remaining 60 days after first opening the bottle.",
    "adverseReactions_original": "None"
}